AI Engines For more Details: Perplexity Kagi Labs You
Antiretroviral Therapy (ART): Didanosine is a key component of combination antiretroviral therapy (ART) regimens used in the management of HIV infection. When used in combination with other antiretroviral medications, such as protease inhibitors or non-nucleoside reverse transcriptase inhibitors, didanosine helps suppress viral replication, reduce HIV-related symptoms, and improve immune function.
Viral Load Suppression: By inhibiting the replication of HIV, didanosine helps reduce the amount of virus (viral load) in the blood and other bodily fluids, thereby slowing the progression of HIV infection and delaying the onset of AIDS (acquired immunodeficiency syndrome).
CD4 Cell Count Elevation: Didanosine therapy is associated with increases in CD4 T-cell counts, which are a key indicator of immune function in individuals with HIV infection. By restoring and preserving CD4 cell counts, didanosine helps strengthen the immune system and reduce the risk of opportunistic infections and AIDS-related complications.
Prevention of Vertical Transmission: Didanosine, when used as part of combination ART during pregnancy and childbirth, has been shown to significantly reduce the risk of vertical transmission of HIV from mother to child. Effective management of HIV during pregnancy with ART can greatly reduce the risk of mother-to-child transmission and improve outcomes for both the mother and the baby.
Adverse Effects: While didanosine is generally well-tolerated, it can cause adverse effects, particularly gastrointestinal side effects such as nausea, vomiting, diarrhea, and abdominal pain. Other potential side effects may include pancreatitis, hepatotoxicity (liver damage), peripheral neuropathy, rash, and metabolic abnormalities. It's important for individuals taking didanosine to report any new or worsening symptoms to their healthcare provider promptly.
Drug Interactions: Didanosine may interact with other medications, including antacids containing aluminum or magnesium, which can reduce its absorption and effectiveness. It's essential for individuals taking didanosine to inform their healthcare provider about all other medications, supplements, and over-the-counter drugs they are using to avoid potential interactions.
Resistance: Like other antiretroviral medications, the development of drug resistance is a concern with didanosine therapy. To minimize the risk of resistance, didanosine should be used in combination with other antiretroviral drugs as part of a comprehensive ART regimen, and adherence to the prescribed treatment regimen is crucial.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Escherichia | genus | Decreases |
| 0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
| 0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
| 0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
| 0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
| 0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
| 0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
| 0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
| 0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
| 0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
| 0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
| 0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
| 0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
| 0 | 1 | Escherichia coli O103 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O111 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O119 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O121 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O145 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O155 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O157 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O177 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O26 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O3 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O43 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O5 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O78 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O86 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O91 | serogroup | Decreases |
| 0 | 1 | Escherichia coli H20 | serotype | Decreases |
| 0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
| 0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
| 0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
| 0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
| 0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
| 0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 0 | 1 | Blautia argi | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 0 | 1 | Coprococcus catus | species | Decreases |
| 0 | 1 | Alistipes sp. dk3624 | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Escherichia coli | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| ADHD | 0.3 | 0.3 | |
| Age-Related Macular Degeneration and Glaucoma | 0.2 | -0.2 | |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.2 | 2 |
| Allergies | 0.4 | 0.4 | |
| Allergy to milk products | 0 | 0.4 | 0 |
| Alopecia (Hair Loss) | 0.5 | 0.5 | |
| Alzheimer's disease | 0.5 | 0.6 | -0.2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0 | 0 | 0 |
| Ankylosing spondylitis | 0.6 | 0.3 | 1 |
| Anorexia Nervosa | 0.3 | 0.1 | 2 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.2 | -1 |
| Asthma | 0.1 | 0.1 | 0 |
| Atherosclerosis | 0 | 0 | |
| Atrial fibrillation | 0.3 | 0.5 | -0.67 |
| Autism | 0.7 | 1.1 | -0.57 |
| Autoimmune Disease | 0.1 | 0.1 | |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| benign prostatic hyperplasia | 0 | 0 | |
| Biofilm | 0.5 | 0.5 | |
| Bipolar Disorder | 0.5 | 0.5 | |
| Brain Trauma | 0.1 | 0.1 | |
| Breast Cancer | 0 | 0 | |
| Cancer (General) | 0.6 | -0.6 | |
| Carcinoma | 0.6 | 0.2 | 2 |
| Celiac Disease | 0.1 | 0.5 | -4 |
| Cerebral Palsy | 0.1 | 0.1 | |
| Chronic Fatigue Syndrome | 0.8 | 1.1 | -0.38 |
| Chronic Kidney Disease | 0.8 | 0.3 | 1.67 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.1 | 1 |
| Chronic Urticaria (Hives) | 0.1 | 0.1 | |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.1 | 3 |
| Cognitive Function | 0.3 | 0.1 | 2 |
| Colorectal Cancer | 0.6 | 0 | 0 |
| Constipation | 0 | 0 | |
| Coronary artery disease | 0.4 | 0.4 | |
| COVID-19 | 1 | 1.1 | -0.1 |
| Crohn's Disease | 1.4 | 0.2 | 6 |
| cystic fibrosis | 0.1 | 0.1 | |
| d-lactic acidosis (one form of brain fog) | 0 | 0 | |
| deep vein thrombosis | 0.1 | 0.1 | 0 |
| Denture Wearers Oral Shifts | 0.1 | 0.1 | |
| Depression | 2.2 | 1 | 1.2 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.4 | 0.1 | 3 |
| Endometriosis | 0.4 | 0 | 0 |
| Eosinophilic Esophagitis | 0.1 | -0.1 | |
| Epilepsy | 0.1 | 0.2 | -1 |
| erectile dysfunction | 0 | 0 | |
| Fibromyalgia | 0.8 | 0.8 | |
| Functional constipation / chronic idiopathic constipation | 0.4 | 0.3 | 0.33 |
| gallstone disease (gsd) | 0.6 | 0.6 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | -0.1 | |
| Generalized anxiety disorder | 0.4 | 0.1 | 3 |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.1 | 0.1 | |
| Graves' disease | 0.2 | 0.1 | 1 |
| Gulf War Syndrome | 0.1 | 0.1 | |
| Halitosis | 0.1 | 0.1 | 0 |
| Hashimoto's thyroiditis | 0.1 | 0.3 | -2 |
| Heart Failure | 0.7 | 0.7 | |
| hemorrhagic stroke | 0.2 | 0.2 | |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0 | 0 | |
| hypercholesterolemia (High Cholesterol) | 0 | 0 | |
| hyperglycemia | 0.1 | 0.2 | -1 |
| Hyperlipidemia (High Blood Fats) | 0.2 | 0.2 | |
| hypersomnia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 0.4 | 0.3 | 0.33 |
| Hypoxia | 0.2 | 0.2 | |
| IgA nephropathy (IgAN) | 0.3 | 0.3 | 0 |
| Inflammatory Bowel Disease | 1.3 | 1.1 | 0.18 |
| Insomnia | 0.1 | 0.1 | 0 |
| Intelligence | 0 | 0 | |
| Intracranial aneurysms | 0.2 | 0.2 | |
| Irritable Bowel Syndrome | 0.2 | 0.3 | -0.5 |
| ischemic stroke | 0.3 | 0 | 0 |
| Liver Cirrhosis | 0.6 | 0.3 | 1 |
| Long COVID | 1.2 | 0.5 | 1.4 |
| Lung Cancer | 0.3 | 0.3 | |
| Lymphoma | 0 | 0 | |
| Mast Cell Issues / mastitis | 0.1 | 0.1 | |
| ME/CFS with IBS | 0.1 | 0.1 | 0 |
| ME/CFS without IBS | 0.4 | 0.6 | -0.5 |
| membranous nephropathy | 0.1 | 0.1 | |
| Menopause | 0.1 | 0.1 | |
| Metabolic Syndrome | 1.4 | 0.5 | 1.8 |
| Mood Disorders | 1.8 | 0.9 | 1 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
| Multiple Sclerosis | 0.7 | 0.8 | -0.14 |
| Multiple system atrophy (MSA) | 0.1 | 0.1 | |
| myasthenia gravis | 0.1 | 0.1 | |
| neuropathic pain | 0.2 | -0.2 | |
| Neuropathy (all types) | 0.1 | 0.3 | -2 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.7 | 0.7 | |
| Obesity | 1 | 1.2 | -0.2 |
| obsessive-compulsive disorder | 0.5 | 0.5 | 0 |
| Osteoarthritis | 1 | 0.1 | 9 |
| Osteoporosis | 0 | 0.1 | 0 |
| pancreatic cancer | 0.1 | 0.1 | 0 |
| Parkinson's Disease | 0.7 | 1.3 | -0.86 |
| Polycystic ovary syndrome | 1.1 | 0.3 | 2.67 |
| Premenstrual dysphoric disorder | 0.2 | -0.2 | |
| primary biliary cholangitis | 0.1 | 0.1 | 0 |
| Primary sclerosing cholangitis | 0.4 | 1.2 | -2 |
| Psoriasis | 0.1 | 0.7 | -6 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.9 | 0.9 | |
| Rosacea | 0.1 | 0.1 | |
| Schizophrenia | 0.5 | 0.2 | 1.5 |
| scoliosis | 0 | 0.2 | 0 |
| Sjögren syndrome | 0.3 | 0.2 | 0.5 |
| Slow gastric motility / Gastroparesis | 0 | 0 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
| Stress / posttraumatic stress disorder | 0.3 | 0.2 | 0.5 |
| Systemic Lupus Erythematosus | 0.9 | 0.6 | 0.5 |
| Tic Disorder | 0.1 | 0.1 | |
| Tourette syndrome | 0.1 | 0.1 | |
| Type 1 Diabetes | 0.3 | 0.1 | 2 |
| Type 2 Diabetes | 0.9 | 0.7 | 0.29 |
| Ulcerative colitis | 1.4 | 0.5 | 1.8 |
| Unhealthy Ageing | 0.7 | 0.2 | 2.5 |
| Vitiligo | 0.3 | 0.2 | 0.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
